AGM
TERN

Alpine Global Management’s Terns Pharmaceuticals TERN Stock Holding History

Alpine Global Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,078
Closed -$109K – 449
2024
Q2 		$109K Buy
+16,078
New +$97.4K 0.02% 398
2023
Q3 		– Sell
-10,655
Closed -$93.2K – 236
2023
Q2 		$93.2K Buy
+10,655
New +$124K 0.03% 175

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alpine Global Management's TERN Position: Q3 2024 in Review

Alpine Global Management sold out of Terns Pharmaceuticals (TERN) in Q3 2024, closing a stake of 16,078 shares — an estimated $109K sold.

Alpine Global Management first reported a position in TERN in Q2 2023 and held it in 2 quarters. The position peaked at $109K in Q2 2024. 156 funds tracked by Wall St. Rank hold TERN as of Q3 2024.

  • Alpine Global Management reported no remaining Terns Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 16,078 Terns Pharmaceuticals shares in Q3 2024, an estimated $109K.
  • Alpine Global Management first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Alpine Global Management's Terns Pharmaceuticals position peaked at $109K in Q2 2024.
  • 156 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.